The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.
A novel biomonitoring method reveals neurotoxic chemical mixtures in human blood
Studies of chemicals in our blood typically capture only a small and unknown fraction of the entire chemical universe. Now, a new approach aims to
October 18, 2024